Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Rodriguez-Osorio

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Kidney Journal|August 8, 2015
Timing of eculizumab therapy for C3 glomerulonephritisLaura Rodriguez-Osorio, Alberto Ortiz
Kidney International|July 1, 2015
Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKDLaura Rodriguez-Osorio, Maria Vanessa Perez-Gomez, Alberto Ortiz
Therapeutic Advances in Drug Safety|August 25, 2015
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionRaquel Esteras, Maria Vanessa Perez-Gomez, Laura Rodriguez-Osorio, et al.
Journal of Bone and Mineral Metabolism|May 17, 2013
Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enemaCarolina Gracia-Iguacel, Emilio Gonzalez-Parra, Laura Rodriguez-Osorio, et al.
Plos One|March 25, 2017
A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patientsRicardo Villa-Bellosta, Laura Rodriguez-Osorio, Sebastian Mas, et al.
Journal of the American Society of Nephrology : JASN|June 22, 2021
TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseAdrian Cordido, Laura Nuñez-Gonzalez, Julio M Martinez-Moreno, et al.
Clinical Kidney Journal|June 27, 2022
Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centresMaría Dolores Arenas Jimenez, Angel Méndez, Karina Furaz, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Kidney Journal|August 8, 2015
Timing of eculizumab therapy for C3 glomerulonephritisLaura Rodriguez-Osorio, Alberto Ortiz
Kidney International|July 1, 2015
Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKDLaura Rodriguez-Osorio, Maria Vanessa Perez-Gomez, Alberto Ortiz
Therapeutic Advances in Drug Safety|August 25, 2015
Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionRaquel Esteras, Maria Vanessa Perez-Gomez, Laura Rodriguez-Osorio, et al.
Journal of Bone and Mineral Metabolism|May 17, 2013
Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enemaCarolina Gracia-Iguacel, Emilio Gonzalez-Parra, Laura Rodriguez-Osorio, et al.
Plos One|March 25, 2017
A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patientsRicardo Villa-Bellosta, Laura Rodriguez-Osorio, Sebastian Mas, et al.
Journal of the American Society of Nephrology : JASN|June 22, 2021
TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseAdrian Cordido, Laura Nuñez-Gonzalez, Julio M Martinez-Moreno, et al.
Clinical Kidney Journal|June 27, 2022
Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centresMaría Dolores Arenas Jimenez, Angel Méndez, Karina Furaz, et al.
Pageof 1